|
Index of reports
> Cases with Lymphadenopathy (3)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vivelle (Estradiol Transdermal) where reactions include lymphadenopathy. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Vivelle side effects in female
Reported by a physician from United States on 2012-02-10
Patient: female
Reactions: Thrombosis, Asthma, Lymphadenopathy, Hypoglycaemia, Osteomyelitis, Lipids Increased, Cerebrovascular Disorder, Peripheral Sensory Neuropathy, Oedema Peripheral, Uterine Leiomyoma, Irritable Bowel Syndrome, Postmenopausal Haemorrhage, Hypoxia, Breast Cancer, Pneumonia, Pain in Extremity, Mastitis, Breast Mass, Hypoaesthesia, Diverticulum Intestinal, Adenomyosis, Diabetic Neuropathy, Staphylococcal Infection, Nervous System Disorder, Gastric Polyps, non-Hodgkin's Lymphoma, Sleep Apnoea Syndrome, Uterine Haemorrhage, Aphasia, Viith Nerve Paralysis, Fibrocystic Breast Disease, Neuropathy Peripheral, Fibromyalgia, Obesity, Depression, Lymphoedema, Transient Ischaemic Attack, Migraine, Abdominal Pain Lower, Type 2 Diabetes Mellitus, Motor Dysfunction, Urinary Tract Infection, Cognitive Disorder, Cystitis, Amnesia, Cerebrovascular Accident, Anxiety, Osteoarthritis, Dysarthria, Diarrhoea, Arthralgia, Dysuria, Flank Pain, Alopecia, Gait Disturbance, Hypertension
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Estraderm
Dosage: 0.5 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1994-04-01
End date: 1997-06-01
Vivelle
Dosage: 0.1 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1997-10-01
End date: 1997-12-01
Provera
Dosage: 2.5 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-03-01
End date: 1994-08-01
Premarin
Indication: Hormone Replacement Therapy
Medroxyprogesterone Acetate
Dosage: 2.5 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-09-01
End date: 2000-02-16
Estraderm
Dosage: 0.1 mg, unk
Start date: 1997-08-01
End date: 2000-02-01
Possible Vivelle side effects in female
Reported by a lawyer from United States on 2012-01-12
Patient: female
Reactions: Asthma, Thrombosis, Lymphadenopathy, Hypoglycaemia, Cerebrovascular Disorder, Lipids Increased, Peripheral Sensory Neuropathy, Uterine Leiomyoma, Irritable Bowel Syndrome, Hypoxia, Postmenopausal Haemorrhage, Breast Cancer, Pneumonia, Pain in Extremity, Breast Mass, Hypoaesthesia, Diverticulum Intestinal, Adenomyosis, Staphylococcal Infection, Diabetic Neuropathy, Nervous System Disorder, Gastric Polyps, non-Hodgkin's Lymphoma, Sleep Apnoea Syndrome, Uterine Haemorrhage, Aphasia, Viith Nerve Paralysis, Neuropathy Peripheral, Fibrocystic Breast Disease, Fibromyalgia, Obesity, Depression, Lymphoedema, Transient Ischaemic Attack, Migraine, Abdominal Pain Lower, Type 2 Diabetes Mellitus, Motor Dysfunction, Cognitive Disorder, Amnesia, Cerebrovascular Accident, Osteoarthritis, Dysarthria, Anxiety, Arthralgia, Diarrhoea, Gait Disturbance, Hypertension
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Estraderm
Dosage: 0.5 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1994-04-01
End date: 1997-06-01
Vivelle
Dosage: 0.1 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1997-10-01
End date: 1997-12-01
Premarin
Indication: Hormone Replacement Therapy
Provera
Dosage: 2.5 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-03-01
End date: 1994-08-01
Estraderm
Dosage: 0.1 mg, unk
Start date: 1997-08-01
End date: 2000-02-01
Medroxyprogesterone Acetate
Dosage: 2.5 mg, unk
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-09-01
End date: 2000-02-16
Possible Vivelle side effects in female
Reported by a physician from United States on 2011-12-02
Patient: female, weighing 68.0 kg (149.7 pounds)
Reactions: Lymphadenopathy, Uterine Leiomyoma, Oedema Peripheral, Arteriosclerosis, Breast Pain, Breast Cancer, Cellulitis, Cardiac Murmur, Osteopenia, Hirsutism, Cerebral Small Vessel Ischaemic Disease, Metastases To Spine, Uterine Disorder, Scar, Bone Pain, Fall, Metastases To Lymph Nodes, Intervertebral Disc Disorder, Dizziness, Oedema, Abdominal Distension, Metastases To Peritoneum, Lymphoedema, Lymph Node Fibrosis, Breast Disorder, Musculoskeletal Pain, Cerebral Atrophy, Osteoarthritis, Anxiety, Mitral Valve Incompetence, Metastases To Bone, Deep Vein Thrombosis
Drug(s) suspected as cause:
Vivelle
Dosage: 0.05mg
Indication: Hormone Replacement Therapy
Start date: 1998-12-30
Combipatch
Dosage: 50/140mcg
Indication: Menopause
Start date: 1998-12-19
Gynodiol
Dosage: 1 mg, unk
Vivelle
Dosage: 0.025mg
Administration route: Topical
Prometrium
Dosage: 100mg
Indication: Hormone Replacement Therapy
Start date: 1998-12-30
Prempro
Dosage: 2.5mg
Indication: Menopause
Start date: 1998-03-13
Vagifem
Dosage: 25 ug, unk
Vivelle
Dosage: .075 mg, unk
Estradiol
Dosage: 1 mg, unk
Gynodiol
Dosage: 0.5 mg, unk
Indication: Hormone Replacement Therapy
Estradiol
Dosage: 0.5mg
Indication: Menopause
Start date: 1999-03-12
Other drugs received by patient: Aldactone; Wellbutrin; Femara; Remeron; Paxil; Dyazide; Spironolactone; Nolvadex; Prozac; Zyban; Xenical; Miacalcin; Aromasin; Alprazolam; Hydrochlorothiazide; Proventil; Zyrtec; Buspar
|
